mTOR: from growth signal integration to cancer, diabetes and ageing
What this study shows
Authoritative review of mTOR from growth-signal integration to disease.
At a glance
| Evidence type | R Review — secondary literature, not a new result Marked R because it is a review or synthesis of existing evidence rather than a new primary result; that is a different form of writing, not a weaker one. |
| Study type | Narrative Review |
| Model system | Review |
| Journal | Nature reviews. Molecular cell biology |
| Year | 2010 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1038/nrm3025 · PMID 21157483 · Free full text (PMC3390257) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Not applicable (review) |
| Target | mTORC1 / mTORC2 |
| Model | Review |
| Effect | Reviews TOR signaling from growth-signal integration to cancer, diabetes and ageing |
In the Atlas
Related topics
More studies on this topic
- Lysosomal mTORC2/PHLPP1/Akt regulate chaperone-mediated autophagy (2015)
- mTOR substrate phosphorylation in growth control (2022)
- A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation (2012)
- A systems study reveals concurrent activation of AMPK and mTOR by amino acids (2016)
Was this page useful?
Thank you. Your answer was counted anonymously.